Recent discussions on X about Novo Nordisk (NVO) have been ignited by the company's disappointing Q2 earnings and a significant cut in its full-year 2025 sales growth forecast. Many users are expressing concern over weakening demand for Wegovy in the U.S. market, compounded by fierce competition from rival weight-loss drugs. The stock's sharp decline, with some noting drops of up to 31% in a single day, has fueled intense debates about future prospects.
Additionally, the FDA approval of Wegovy for treating metabolic-associated steatohepatitis (MASH), a serious liver disease, has sparked a mix of intrigue and optimism among some on the platform. There’s curiosity about whether this development could offset recent setbacks and bolster the company’s position in the obesity care market. The conversation remains dynamic as investors weigh both the challenges and potential catalysts ahead.
Note: This discussion summary was generated from an AI condensation of post data.
Novo Nordisk Congressional Stock Trading
Members of Congress have traded $NVO stock 12 times in the past 6 months. Of those trades, 8 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $NVO stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $50,000 on 08/19.
- REPRESENTATIVE SCOTT FRANKLIN has traded it 6 times. They made 6 purchases worth up to $160,000 on 08/04, 03/27 and 0 sales.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/09 and 1 sale worth up to $15,000 on 07/10.
- REPRESENTATIVE LAUREL M. LEE sold up to $15,000 on 05/08.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/20.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Novo Nordisk Hedge Fund Activity
We have seen 688 institutional investors add shares of Novo Nordisk stock to their portfolio, and 959 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KINGSTONE CAPITAL PARTNERS TEXAS, LLC added 10,001,898 shares (+301443.6%) to their portfolio in Q2 2025, for an estimated $690,330,999
- AMUNDI removed 4,938,507 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $340,855,753
- FMR LLC added 4,308,228 shares (+44.7%) to their portfolio in Q2 2025, for an estimated $297,353,896
- TWO SIGMA ADVISERS, LP removed 3,465,100 shares (-71.3%) from their portfolio in Q2 2025, for an estimated $239,161,202
- NUVEEN, LLC removed 3,236,504 shares (-60.7%) from their portfolio in Q2 2025, for an estimated $223,383,506
- D. E. SHAW & CO., INC. removed 2,582,572 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $178,249,119
- JPMORGAN CHASE & CO removed 2,169,545 shares (-39.5%) from their portfolio in Q2 2025, for an estimated $149,741,995
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Novo Nordisk Analyst Ratings
Wall Street analysts have issued reports on $NVO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 08/19/2025
To track analyst ratings and price targets for Novo Nordisk, check out Quiver Quantitative's $NVO forecast page.
Novo Nordisk Price Targets
Multiple analysts have issued price targets for $NVO recently. We have seen 2 analysts offer price targets for $NVO in the last 6 months, with a median target of $67.0.
Here are some recent targets:
- Michael Nedelcovych from TD Cowen set a target price of $70.0 on 08/19/2025
- Evan David Seigerman from BMO Capital set a target price of $64.0 on 04/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
